NCT03942328View on ClinicalTrials.gov

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

September 19, 2019

Primary Completion Date

August 31, 2027

Study Completion Date

February 29, 2028

Conditions
Stage III Hepatocellular Carcinoma AJCC v8Stage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Unresectable Hepatocellular CarcinomaUnresectable Intrahepatic Cholangiocarcinoma
Interventions
BIOLOGICAL

Atezolizumab

Given IV

BIOLOGICAL

Bevacizumab

Given IV

RADIATION

External Beam Radiation Therapy

Undergo high-dose EBRT

PROCEDURE

Pheresis

Undergo apheresis

BIOLOGICAL

Pneumococcal 13-valent Conjugate Vaccine

Given IM

BIOLOGICAL

Therapeutic Autologous Dendritic Cells

Given IT

BIOLOGICAL

Tiragolumab

Given IV

PROCEDURE

Esophagogastroduodenoscopy

Undergo EGD

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo urine and blood sample collection

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER